Last reviewed · How we verify
NCT00340535
Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering
trial in Normal Physiology in 100 participants. Completed in 4 March 2021.
1 October 2004
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 23 June 2004 |
| Primary completion | 1 October 2004 |
| Estimated completion | 4 March 2021 |
| Sites | 1 location across United States |
Conditions studied
- Normal Physiology — all drugs for Normal Physiology →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 18 to 90, any sex, with Normal Physiology. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine whether genetic differences among individuals affect blood levels of certain chemicals called DBPs after showering. Chemicals such as chlorine and ozone are used to kill germs in water. These chemicals may react with organic matter in the water and form other chemicals called disinfection byproducts, or DBPs. Although people are usually exposed to DBPs by drinking tap water, these chemicals may also penetrate the body during showering. This study will see whether the levels of DBPs after showering vary among individuals depending on differences in genes that code for enzymes called GSTT1, CYP2D6, and CYP2E1, which break down DBPs. This study, sponsored by the Centers for Disease Control and Prevention and the National Institutes of Health, is conducted at the University of Pittsburgh's Center for Clinical Pharmacology. Healthy adults between 18 and 45 years of age who do not smoke cigarettes and are not taking any medicines may be eligible for this study. Candidates are screened with a medical history and blood and urine tests. Participants are given a diary to record the foods they eat and how much water they drink during the 2 days before their study appointment. The following activities are scheduled on the appointment day: * Measurements of blood pressure, height, and weight, and pregnancy test for women * Questions about alcohol consumed and medications taken in the last 48 hours * Review of food and water diary * Interview for demographic information (name, address, date of birth, etc.) and other information, such as sex, height, weight. Subjects are also asked about anything, such as exercise, that might affect their breathing, since breathing problems are a rare side effect of chlorzoxazone, a drug used in this study. * Urine sample collection * Blood draw and insertion of a small catheter (plastic tube) to allow for additional blood draws during the test procedure without having repeated needle sticks * 10-minute shower in a private bathroom * Blood sample collection 10 minutes after the shower and again at 30 minutes after the shower * Dose of chlorzoxazone (a drug used to treat muscle pain) * Interview about subject's exposure to water * Light breakfast * Blood and urine collections 2 hours after the chlorzoxazone dose * Lunch * Observation for drug side effects for 2 hours, or longer if needed Seven blood samples totaling 75 milliliters (about 5 tablespoonfuls) of blood are collected during this study. The blood is tested for chemicals called trihalomethanes to see how they are broken down. The urine samples are tested for chemicals called haloacetic acids, which are found in tap water after it has been treated with chlorine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00340535
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Normal Physiology
Currently open trials in the same condition.
- NCT06561828 — Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making · EARLY_PHASE1 · recruiting
- NCT05666739 — NIEHS Repository of Stored Biological Samples for Future Use · recruiting
- NCT05829044 — Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms · NA · recruiting
- NCT06050603 — MRI Guided Closed-loop TMS-EEG · NA · recruiting
- NCT05545306 — The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure · NA · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00340535 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 5 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00340535.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing